×
Videos Agriculture Health Business Education Positive Breaking Sports Ansuni Gatha Advertise with Us Catch The Rainnew More
HOME >> HEALTH

HEALTH

FABISPRAY IS THE FIRST NASAL SPRAY FOR COVID-19 PATIENTS IN INDIA.

by admin

Date & Time: Feb 09, 2022 5:00 PM

Read Time: 2 minute

HIGHLIGHTS:
  • Glenmark, global pharma has launched Nitric Oxide Nasal Spray (FabiSpray) in India
  • Nitric Oxide Nasal Spray decreases viral load and hastens RT-PCR negative, resulting in recovery
  • NONS is applied topically, it is quite safe

Glenmark, a Mumbai-based global pharma firm known for its innovation, has launched Nitric Oxide Nasal Spray (FabiSpray) in India in collaboration with SaNOtize for the treatment of adult COVID-19 patients. As part of the fast approval procedure, Glenmark acquired manufacturing and marketing authorization for Nitric Oxide Nasal Spray from India's drug authority, Drugs Controller General of India.

Phase 3

"The major objectives of the Phase 3 study in India were reached, with viral load reductions of 94 percent in 24 hours and 99 percent in 48 hours. In COVID-19 patients, nitric oxide nasal spray (NONS) was found to be safe and well tolerated. Glenmark will offer NONS under the FabiSpray brand "the official statement states.

How does the Nasal Spray work according to the firm!

When Nitric Oxide Nasal is sprayed over nasal mucosa, the firm claims it serves as a physical and chemical barrier against the virus. "The COVID-19 virus is destroyed by FabiSpray in the upper airways. It has been shown to have antimicrobial characteristics and to have a direct virucidal effect on SARS-CoV-2. NONS serves as a physical and chemical barrier against the virus, stopping it from incubating and spreading to the lungs, when sprayed over nasal mucosa "The statement reads.

Glenmark Pharmaceuticals Ltd's Chief Commercial Officer Robert Crockart described the spray as an effective and safe antiviral treatment for COVID-19, saying, "We are convinced it will offer patients a much needed and timely therapy choice."

Dr. Srikanth Krishnamurthy view on NONS

One of the study's Principal Investigators, Dr. Srikanth Krishnamurthy, said, "I've had a chance to look over the study's findings. When used early in COVID 19 infection, Nitric Oxide Nasal Spray decreases viral load and hastens RT-PCR negative, resulting in recovery. Most importantly, lowering viral load with NONS has the ability to break the transmission chain. Last but not least, because NONS is applied topically, it is quite safe, making this therapeutic approach highly appealing ".

Also Read: ZYCOV-D: INDIA’S FIRST PAINLESS NEEDLE-FREE VACCINE LAUNCHED IN PATNA

You May Also Like


Comments


No Comments to show, be the first one to comment!


Leave a comment

Your email address will not be published. Required fields are marked *